SGLT2 Inhibitors and Continuation of Renin Angiotensin Blockade
0:00
21:23
Dr. Briggs and Brendon Neuen discuss his paper in the December issue of JASN. This article on the CREDENCE and EMPA-CKD clinical trials shows that SGLT2 inhibitors allow more consistent use of RAS blockade in patients with declining renal function.
More episodes from "Journal of the American Society of Nephrology (JASN)"
Don't miss an episode of “Journal of the American Society of Nephrology (JASN)” and subscribe to it in the GetPodcast app.